BridgeBio reports breakthrough results in Phase 3 achondroplasia trial
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
Achondroplasia is a genetic condition driven by FGFR3 that affects more than stature alone
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
PBGENE-DMD is designed to permanently correct mutations in the dystrophin gene between exons 45 and 55, the “hot-spot” region affecting roughly 60% of DMD patients
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
Motorica India conducted a specialised masterclass led by Shumaev, centred on real-life rehabilitation scenarios and personalised therapy programs before and after prosthetic fitting
The unveiling marks Time Medical India’s entry into next-generation helium-free MRI technology
The board highlighted ongoing investments in Radiopharma, CDMO Sterile Injectables, and CRDMO businesses
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children
Subscribe To Our Newsletter & Stay Updated